trending Market Intelligence /marketintelligence/en/news-insights/trending/JBSj0kQmLgVoFp71spgBFg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

Eisai Co. Ltd. and Purdue Pharma LP are seeking U.S. Food and Drug Administration approval for lemborexant as a treatment for insomnia, a sleep disorder.

The new drug application submitted to the regulator was based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

Lemborexant works by acting the orexin neurotransmitter system, which regulates a person's wakefulness.

Tokyo's Eisai and Stamford, Conn.-based privately held company Purdue Pharma are jointly developing the therapy for sleep-wake disorders. Lemborexant is also slated for a phase 2 study in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia.